LOGIN  |  REGISTER

embecta to Participate in Upcoming Investor Conferences

February 08, 2023 | Last Trade: US$14.62 0.43 -2.86

PARSIPPANY, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following upcoming investor conferences:

2023 BTIG Medical Technology Conference

  • Management will host virtual investor meetings on Wednesday, February 15, 2023.

2023 JP Morgan Global High Yield and Leveraged Finance Conference

  • Management will host a presentation session on Monday, March 6, 2023, at 2:00 p.m. Eastern Time (ET) in Miami, FL.

2023 Oppenheimer 33rd Annual Healthcare Conference

  • Management will host a virtual presentation session on Tuesday, March 14, 2023, at 8:00 a.m. ET. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com.

About embecta 
embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.

CONTACTS 

Investors:
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR

Media:
Christian Glazar
Sr. Director, Corporate Communications 
908-821-6922 
Contact Media Relations

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB